Enveric Biosciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Enveric Biosciences, a biotechnology company, reported substantial doubt about its ability to continue as a going concern despite recent capital raises, as it focuses on preclinical development of its lead neuroplastogen candidate, EB-003.
NASDAQ
Enveric Biosciences reports its 10-K filing, highlighting ongoing losses and substantial doubt about its ability to continue as a going concern, despite advancements in its neuroplastogenic therapeutic pipeline.
NASDAQ
Enveric Biosciences has adopted a comprehensive Corporate Code of Conduct and Ethics and Whistleblower Policy to ensure ethical business practices and provide a confidential reporting mechanism for violations.